CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Dopamine Hydrochloride Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2017-11-06. Latest FDA row update: 2026-10-02.
FDA lists 11 package records, with companies: Baxter Healthcare, Baxter Healthcare Corporation, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company. Package NDCs: 0143-9252-25, 0143-9254-25, 0338-1005-02, 0338-1005-03, 0338-1007-02, 0338-1007-03, 0409-0042-12, 0409-1858-12, 0409-5820-01, 0409-7809-24, 0409-9104-20.
FDA shortage reason: Demand increase for the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Baxter Healthcare | 0338-1007-02 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-1007-03 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-1005-02 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-1005-03 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03) | Available | 2026-10-02 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9252-25 | Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9254-25 | Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25) | Unavailable | 2026-09-18 |
| Hospira, Inc., a Pfizer Company | 0409-0042-12 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1858-12 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-7809-24 | Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-5820-01 | Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9104-20 | Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20) | Available | 2026-09-22 |
Source facts
Grouped generic ingredient: Dopamine Hydrochloride Injection · 11 package records
Therapeutic categories: Cardiovascular
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.